As many in the prostate cancer community will be aware, there has been a major battle ongoing over whether the drug bevacizumab (Avastin) should continue to be approved by the U.S. Food & Drug Administration (FDA) for the treatment of women with metastatic breast cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Centers for Medicare and Medicaid Services, CMS, coverage, off-label | Leave a comment »
